TYMS

Across TCGA pan-cancer cohorts, TYMS Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TYMS data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TYMS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TYMS expression acts as an unfavorable survival marker.

BLCA, UCS, and COAD are the cancer types where TYMS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.078	0.594	<.001	9	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
COAD	DFS	Median	II,III,IV	0.408	0.759	.016	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TYMS–BLCA (DFS)

Open the BLCA breakdown →